Parameswaran Venugopal to Antibodies, Monoclonal, Murine-Derived
This is a "connection" page, showing publications Parameswaran Venugopal has written about Antibodies, Monoclonal, Murine-Derived.
Connection Strength
0.466
-
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
Score: 0.327
-
Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003 Nov; 1(11):658-60; discussion 660.
Score: 0.050
-
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
Score: 0.033
-
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Feb; 10(2):134-6.
Score: 0.022
-
GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma. 2008 Sep; 49(9):1681-92.
Score: 0.018
-
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
Score: 0.016